Real-World Performance of MRI-TRUS Fusion Biopsy in a Canadian Tertiary Centre: What Drives a Positive Diagnosis?

Abstract

Get full access to this article

View all access options for this article.

References

Kasivisvanathan

Rannikko

Borghi

, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777.

Thompson

Kamali

Abdolell

, et al. The diagnostic yield of MRI–transrectal US fusion prostate biopsy in men with suspected prostate cancer. Can Assoc Radiol J. In press.

Oerther

Nedelcu

Engel

, et al. Update on PI-RADS Version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis. Radiology. 2024;312(2):e233337.

Turkbey

Rosenkrantz

Haider

, et al. PI-RADS v2.1: 2019 update of the Prostate Imaging Reporting and Data System. Eur Urol. 2019;76(3):340-351.

Chang

Reinhold

Kirkpatrick

IDC

, et al. Canadian Association of Radiologists Prostate MRI white paper. Can Assoc Radiol J. 2022;73(4):626-638.

Kinnaird

Luger

Cash

, et al. Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis: the OPTIMUM randomized clinical trial. JAMA. 2025;333(19):1679-1687.

Wagner

Samji

. Limited utility of dynamic contrast enhancement imaging sequences within the PI-RADS v2.1 classification scheme: a retrospective cross-sectional study of MRI reports. Can Assoc Radiol J. 2025;76(1):87-93.

Schieda

Nisha

Hadziomerovic

, et al. Comparison of positive predictive values of biparametric and multiparametric MRI-directed transrectal US-guided targeted prostate biopsy. Radiology. 2024;311(3):e231383.

Westphalen

McCulloch

Anaokar

, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers. Radiology. 2020;296(1):76-84.